Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Novel

Drug and asset intelligence for Novel with 18 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
18
Catalysts
0
Stage
Development stage unavailable

Sponsor company

oncology therapeutics market →

Mechanism of action

Photodynamic Therapy

Recent signals(18)

ClinicalAugust 6, 2026

Novel MRI Methods for Liver Disease Biomarkers Under Evaluation

A study is assessing new MRI techniques for quantifying blood perfusion and tissue microstructure in liver diseases.

StrategyAugust 1, 2026

Novel DPP-LIP-SA Composite Shows Promise in Treating UVB-Induced Skin Photoaging

A liposome-hydrogel composite delivery system significantly alleviated UVB-induced skin photoaging in mice by enhancing the stability and bioactivity of deer placenta polypeptides.

ClinicalAugust 1, 2026

Novel microRNA Biomarker Approach for Renal Osteodystrophy Treatment

A study is investigating a microRNA approach as a non-invasive biomarker for assessing bone turnover in renal osteodystrophy.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

Colorectal Cancer →
Gastric Cancer →
Liver Fibrosis →
Lung Cancer →
Parkinson's Disease →
Prostate Cancer →

Therapeutic areas

Antitumor Agents →
Cannabinoids →
CDK7 Inhibition →
Colorectal Cancer →
Dermatology →
Gastric Cancer →
Hepatology →
Imaging →
Liver Fibrosis →
Lung Cancer →
Nanomedicine →
Nephrology →
Neurology →
Nutraceuticals →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.

ClinicalJuly 31, 2026

Novel ultrasound technique for managing cystic fibroids during pregnancy shows promise

A novel ultrasound-guided aspiration technique for large cystic fibroids was successfully performed in pregnant patients, allowing continuation of pregnancy.

ClinicalJuly 31, 2026

Novel Rh-catalysed method yields potent antitumor phenanthridinone derivatives

A series of phenanthridinone derivatives were synthesized, with compound 3a showing potent TDP1 inhibitory activity and compound 3c demonstrating strong TOP1 inhibition and antitumor efficacy in vivo.

StrategyJuly 25, 2026

Novel PLC-SNEDDS Enhances Oral Bioavailability of Cannabidiol Significantly

A new phospholipid complex self-nanoemulsifying drug delivery system (CBD-PLC-SNEDDS) significantly enhances the oral bioavailability of cannabidiol to 92%.

ClinicalJuly 19, 2026

Novel CMC/CeO2 Nanocarriers Enhance Quercetin Delivery in Lung Cancer Cells

A new CMC-based nanocarrier system co-loaded with CeO2 and CQDs shows improved quercetin delivery and anticancer activity against A549 lung cancer cells.

ClinicalJuly 19, 2026

Novel Imaging Biomarker PPAT Thickness Predicts Prostate Cancer in Gray Zone Patients

Normalized periprostatic adipose tissue thickness is introduced as a novel imaging biomarker for predicting prostate cancer in patients with PI-RADS score 3 and PSA levels of 4-10 ng/mL.

ClinicalJuly 18, 2026

Novel MOF P/ZnO Nanocomposite Shows Promise for Targeted Cancer Therapy

A new metal-organic framework (MOF P) integrated with ZnO nanoparticles shows effective cancer cell apoptosis and reduced viability.

CompetitiveJuly 14, 2026

Novel CDK7 Inhibitor 7a Shows Potent Antitumor Activity in Colorectal Cancer Models

Compound 7a is a highly selective CDK7 inhibitor with an IC50 of 1.9 nM, demonstrating significant antitumor efficacy in HCT116 models.

ClinicalJuly 10, 2026

Novel ALA-HPO hybrids show enhanced efficacy in photodynamic therapy for superficial tumors

The study presents ALA-HPO derivatives that significantly improve PpIX yield and phototoxicity in treating superficial tumors.

ClinicalJuly 9, 2026

Novel compound AG3 shows promise for targeting p53-Y220C mutation in gastric cancer

AG3, a compound with zinc chelation and Michael acceptor properties, effectively reactivates p53-Y220C in gastric cancer cells.

ClinicalJuly 8, 2026

Novel Remote Rehab Technique for Parkinson's Disease in Veterans

A new remote dynamic cycling rehabilitation technique is being tested for its efficacy in Parkinson's disease patients.

StrategyJuly 2, 2026

Novel GA/βCD/VDC Nanovehicle Enhances Oral Bioavailability of Cholecalciferol

The GA/βCD/VDC nanovehicle significantly enhances the oral bioavailability of cholecalciferol, improving absorption and retention in tissues.

ClinicalJune 23, 2026

Novel PSMA-targeted Imaging and SABR for Recurrent Prostate Cancer

A clinical trial is investigating the use of PSMA-targeted PET imaging combined with MR imaging to localize recurrent prostate cancer for targeted stereotactic ablative radiotherapy.

ClinicalJune 22, 2026

Novel Diclofenac Potassium Lollipop for Pediatric Postoperative Pain Management

A clinical trial evaluated a weight-adjusted diclofenac potassium lollipop for managing postoperative pain in children after adenotonsillectomy.

ClinicalJune 21, 2026

Novel KRAS(G12V)-targeting peptide shows potent activity against colorectal cancer cells

Peptide-1 demonstrated strong binding affinity to KRAS G12V and potent antiproliferative effects in colorectal cancer cell lines.

ClinicalJune 20, 2026

Novel Oral Nanoemulsion Targets Hepatic Stellate Cells in Liver Fibrosis Treatment

A vitamin A-functionalized self-nanoemulsifying drug delivery system effectively targets hepatic stellate cells in liver fibrosis.

Obstetrics →
Oncology →
Pain Management →
Parkinson's Disease →
Pediatric →
Photodynamic Therapy →
Prostate Cancer →
Renal Osteodystrophy →
Skin Aging →
Uterine Fibroids →
Vitamin D →